Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Washington University School of Medicine Identifier:
First received: May 12, 2006
Last updated: January 26, 2017
Last verified: January 2017
This study investigates the feasibility and safety of delivering radiation therapy only to part of the breast, (the tumor bed and selected areas) rather than the whole breast, for patients with early stage breast cancer.

Condition Intervention Phase
Breast Neoplasms
Radiation: Partial Breast Irradiation (PBI)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer: A Phase I/II Feasibility Study

Resource links provided by NLM:

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan [ Time Frame: Within 1 year of protocol registration ]
    -The study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her.

  • Feasibility of PBI Directed External Radiotherapy as Measured by Development of Histological Fat Necrosis or Other Grade 4 Skin or Grade 4 Subcutaneous Toxicity, or Requires Surgery for the Skin/Subcutaneous Toxicity [ Time Frame: Within 1 year of protocol registration ]
    -The study will be deemed infeasible if more than 4 patients develop histological fat necrosis or other grade 4 skin or grade 4 subcutaneous toxicity, or requires surgery for her skin or subcutaneous toxicity

Secondary Outcome Measures:
  • Incidence and Severity of Cutaneous Toxicity [ Time Frame: Up to 5 years ]
  • Incidence of Breast Fibrosis [ Time Frame: Up to 5 years ]
  • Incidence of Fat Necrosis [ Time Frame: Up to 5 years ]
  • Cosmetic Outcome [ Time Frame: Up to 5 years ]
  • Local Control Rate [ Time Frame: Up to 5 years ]
  • Regional Control Rate [ Time Frame: Up to 5 years ]
  • Distant Control Rate [ Time Frame: Up to 5 years ]

Enrollment: 100
Study Start Date: February 14, 2006
Estimated Study Completion Date: April 16, 2017
Primary Completion Date: April 16, 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1 (36 Gy)
36 Gy in 9 fractions BID x 4 1/2 treatment days
Radiation: Partial Breast Irradiation (PBI)
Experimental: Cohort 2 (40 Gy)
40 Gy in 10 fractions BID over 5 treatment days
Radiation: Partial Breast Irradiation (PBI)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Histologic Documentation:

    • Patients will have histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast cancer.
    • Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.
    • Tubular, mucinous and medullary variant histologies of infiltrating ductal carcinoma are permitted.
    • Low-grade DCIS (I and II) of 2 cm or less with histologically negative margins of at least 2 mm margins (or a negative re-excision) are permitted.
    • Women age 70 years or older with T1 invasive ductal carcinoma which are estrogen-receptor positive (ER+) with clinically negative axillary nodes who do not undergo surgical lymph node evaluation are also eligible if patient will take hormonal therapy.
    • Patients with T1N0 (i+) tumors on sentinel lymph node mapping or dissection (i.e. is tumor deposit is 0.2mm or less, regardless of whether the deposit is detected by IHC or H&E staining) will also be eligible, provided that completion axillary dissection has been performed to confirm N0 status.
    • In the case where invasive cancer is present, the invasive cancer's pathology will be used regardless if DCIS is also present.
  2. Prior Treatment: Patient may have been treated with adjuvant chemotherapy. Patients may be on adjuvant hormonal therapy or begin hormonal therapy following XRT at the discretion of the medical oncologist.

    Radiation therapy should begin within:

    • 4-12 weeks from definitive surgical procedure
    • 2-6 weeks after chemotherapy, if chemotherapy given first
    • Radiation cannot be delivered concurrently with chemotherapy.
  3. Age >= 18 years of age
  4. ECOG Performance Status 0-2.
  5. Signed Informed Consent

Exclusion Criteria

The following guidelines are to assist physicians in selecting patients for whom protocol therapy is safe and appropriate. Physicians should recognize that the following may seriously increase the risk to the patient entering this protocol. Patients who meet the following criteria should not be entered in this study:

1a Multicentric IDC of the breast defined as discontiguous tumors separated by at least 5 cm of uninvolved tissue; alternatively, discontiguous tumors that are clinically or mammographically within separate breast quadrants or subareolar central region.

  1. b Multifocal IDC of the breast, defined as discontiguous discrete foci of invasive carcinoma, separated by uninvolved intervening tissue, but within an overall span of 5cm, or within the same breast quadrant or subareolar central region.
  2. Tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement
  3. Histological evidence of:

    1. Lymphovascular invasion: as defined by a tumor embolus present in an endothelial-lined space; cases with tumor emboli present in a space not lined by endothelial cells but otherwise very suspicious for an angiolymphatic space were also considered ineligible.
    2. EIC (Extensive Intraductal Component): defined as the presence of intraductal carcinoma both within the primary infiltrating ductal tumor (comprising at least 25% of the tumor area) and intraductal carcinoma present clearly beyond the edges of the invasive tumor, or as a predominantly intraductal tumor with one or more areas of focal invasion 7, 55.
    3. Invasive Lobular Carcinoma
    4. Infiltrating carcinoma with mixed ductal and lobular features: cases with ambiguous or mixed histologic features that showed positive E-cadherin staining throughout the tumor by immunohistochemistry were classified as ductal type and considered eligible 56, 57.
    5. Infiltrating papillary carcinoma
    6. Margins: In-situ or invasive carcinoma present less than 2 mm from the inked resection margin.
  4. History of cosmetic or reconstructive breast surgery
  5. Psychiatric illness which would prevent the patient from giving informed consent. Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or connective tissue diseases (lupus, systemic sclerosis or other collagen vascular diseases) which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
  6. Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and considered by their physician to be at less than 5% risk of relapse within three years.
  7. Patients with diffuse (> 1 quadrant or > 5cm) suspicious microcalcifications
  8. Women who are pregnant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00325598

United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: Imran Zoberi, M.D. Washington University School of Medicine
  More Information

Additional Information:
Responsible Party: Washington University School of Medicine Identifier: NCT00325598     History of Changes
Other Study ID Numbers: 05-1053 / 201103235
Study First Received: May 12, 2006
Results First Received: September 19, 2016
Last Updated: January 26, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on April 21, 2017